Price
CHART BY
Frequently asked questions
What is PTC Therapeutics's market capitalization?
The market capitalization of PTC Therapeutics is $5.96B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for PTC Therapeutics?
PTC Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.594. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for PTC Therapeutics's stock?
Currently, 15 analysts cover PTC Therapeutics's stock, with a consensus target price of $99.29. Analyst ratings provide insights into the stock's expected performance.
What is PTC Therapeutics's revenue over the trailing twelve months?
Over the trailing twelve months, PTC Therapeutics reported a revenue of $1.01B.
What is the EBITDA for PTC Therapeutics?
PTC Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $172.03M. EBITDA measures the company's overall financial performance.
What is the free cash flow of PTC Therapeutics?
PTC Therapeutics has a free cash flow of -$39.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does PTC Therapeutics have, and what sector and industry does it belong to?
PTC Therapeutics employs approximately 991 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of PTC Therapeutics's shares?
The free float of PTC Therapeutics is 79.72M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.96B
- EPS (TTM)
- -$0.594
- Free Float
- 79.72M
- Revenue (TTM)
- $1.01B
- EBITDA (TTM)
- $172.03M
- Free Cashflow (TTM)
- -$39.71M
Pricing
- 1D span
- $69.28$71.78
- 52W span
- $56.55$90.86
Analyst Ratings
The price target is $99.29 and the stock is covered by 15 analysts.
Buy
11
Hold
3
Sell
1
Information
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
- Employees
- 991
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- PTCT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet